Investigational EGFR x HER3 therapy supports Phase III dose after lung cancer trial

by International Association for the Study of Lung Cancer

edited by Sadie Harley, reviewed by Andrew Zinin

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

proofread

The GIST Add as preferred source

An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection of the 2.5 mg/kg dose for evaluation in the global Phase III IZABRIGHT-Lung01 registrational study.

These results will be presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) in Seoul, Republic of Korea.

Results from the randomized dose-expansion cohort of the global Phase I study showed increasing clinical activity with higher dose levels. At the recommended Phase III dose of 2.5 mg/kg, the objective response rate reached 33.3%, the confirmed objective response rate was 29.6%, and median progression-free survival was 6.9 months.

All enrolled patients had previously progressed on a third-generation EGFR inhibitor, and nearly two-thirds had also received platinum-based chemotherapy. Mandatory primary G-CSF prophylaxis was associated with an improved hematologic safety profile compared with previously reported experience.

Overall, the investigational therapy demonstrated a manageable safety profile. No treatment-related deaths were observed, and only one patient discontinued treatment because of a treatment-related adverse event.

"These findings support continued development of iza-bren and provide the rationale for advancing the 2.5 mg/kg regimen into the global phase 3 IZABRIGHT-Lung01 trial for patients with previously treated EGFR-mutated NSCLC," said Alexander Spira, M.D., NEXT Oncology Virginia and Virginia Cancer Specialists, Fairfax, Virginia.

Clinical categories

OncologyClinical pharmacology Provided by International Association for the Study of Lung Cancer Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Investigational EGFR x HER3 therapy supports Phase III dose after lung cancer trial (2026, September 12) retrieved 12 September 2026 from https://medicalxpress.com/news/2026-09-egfr-her3-therapy-phase-iii.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.